Freenome Company Profile

05:37 EDT 20th September 2019 | BioPortfolio

Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through early detection and intervention. Since launching in 2014, the company has raised more than $70 million from leading technology and healthcare investors. For more information, please visit Freenome online at:

News Articles [21 Associated News Articles listed on BioPortfolio]

Freenome Snags $160M to Boost Blood Test for Early Cancer Detection

Freenome, one of the rivals racing to detect the earliest signs of cancer through blood tests, announced Wednesday it has raised $160 million in a Series B funding round. The money boosts Freenome’s...

ADC Therapeutics, Freenome Enter Biomarker Development Collaboration

ADC Therapeutics to employ Freenome's multiomics platform to identify biomarkers that correlate with clinical response to ADCT-402

Freenome inks biomarker development deal with ADC Therapeutics

Freenomeâs multiomics platform is being used in a Phase II clinical trial to help identify patients most likely to respond to ADC Therapeuticsâ antibody drug conjugate.

Freenome Secures $160 Million to Advance Cancer Detection Blood Test

Following additional study, Freenome said it plans to seek regulatory approval under the Parallel Review Program, the first application of its platform in colorectal cancer screening.

Funding round pulls in $160M for Freenome

A round of Series B funding has pulled in $160 million for liquid biopsy startup Freenome, which plans to use the proceeds to -More- 

Freenome secures £128m funds for multiomics cancer blood testing platform

With the latest series B funding, led by RA Capital Management and Polaris Partners, Freenome’s total financing reached to $238m (£190.8m). The funding round saw participation from the The post Fr...

Freenome partners with ADC on biomarker development

Freenome and ADC Therapeutics agreed to collaborate on a biomarker development program that will identify patients who are li -More- 

Freenome raises $160m to advance blood testing platform that de-risks drug development, says CEO

Freenome is working with a CRO as part of a clinical trial evaluating the companyâs multi-omics blood testing platform â which the CEO says helps de-risk drug development by characterizing likely re...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test

Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this study is to ...

Companies [2 Associated Companies listed on BioPortfolio]


Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating ...

Freenome, Inc.

Freenome is an AI genomics company on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent their diseases. By applying advanced machine ...

More Information about "Freenome" on BioPortfolio

We have published hundreds of Freenome news stories on BioPortfolio along with dozens of Freenome Clinical Trials and PubMed Articles about Freenome for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Freenome Companies in our database. You can also find out about relevant Freenome Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record